Regeneron Q1 revenue down 1% to $3.15B; Non-GAAP EPS $9.55; new $3B buyback

REGENERON PHARMACEUTICALS, INC.

2024-Q1 EPS reported $6.27 revenue$3,145,000,000

GAAP net income $722M ($6.27 diluted EPS) vs $818M ($7.17) YoY; Non-GAAP net income $1,116M ($9.55).
Dupixent global net sales up 24% to $3.08B; EYLEA HD U.S. sales $200M, total EYLEA/HD $1.4B (down 2%).
Libtayo global net sales up 45% to $264M; Sanofi collaboration revenue up 14% to $910M.
Board authorized new $3.0B share repurchase; Q1 repurchases $298M, $1.2B remaining under prior program.
2024 guidance updated: GAAP R&D $4.92-5.17B, GAAP SG&A $2.94-3.09B; gross margin unchanged.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

REGENERON PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.

Period: first quarter of 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended March 31, 2024.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001804220-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.